Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial

医学 安慰剂 耐受性 内科学 西地那非 安慰剂对照研究 双盲 临床试验 肺动脉高压 临床终点 不利影响 病理 替代医学
作者
Stephan Rosenkranz,Jeremy Feldman,Vallerie V. McLaughlin,Franz Rischard,Tobias Lange,R. James White,Andrew J. Peacock,Felix Gerhardt,Ramin Ebrahimi,Gabriel Brooks,Carol Satler,Robert P. Frantz
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:10 (1): 35-46 被引量:23
标识
DOI:10.1016/s2213-2600(21)00032-1
摘要

Background Data obtained in human lung tissue and preclinical models suggest that oxidative stress and increased apoptosis signal-regulating kinase 1 (ASK1) activity might have a prominent role in the pathobiology of pulmonary arterial hypertension (PAH). The purpose of this study was to determine the efficacy, safety, and tolerability of the ASK1 inhibitor selonsertib compared with placebo in patients with PAH. Methods We did a randomised, double-blind, placebo-controlled, phase 2 trial at 46 centres located in Canada, France, Germany, Italy, the Netherlands, Spain, the UK, and the USA. Participants were aged 18–75 years and had an established diagnosis of idiopathic or hereditary PAH, or PAH associated with connective tissue disease, drugs or toxins, human immunodeficiency virus, or repaired congenital heart defects. Patients were stratified by PAH aetiology and background therapy, and randomly assigned (1:1:1:1) using an interactive voice-response or web-response system to placebo or selonsertib 2 mg, 6 mg, or 18 mg administered orally once daily. Both placebo and selonsertib were in tablet form. The primary efficacy endpoint was change in pulmonary vascular resistance, measured by right heart catheterisation, from baseline to week 24 in the full analysis set. Pair-wise comparisons between each of the selonsertib groups and the placebo group were made with a stratified Wilcoxon (van Elteren) rank sum test for participants without major protocol deviations who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT02234141. Findings Between Dec 3, 2014, and Nov 13, 2015, 151 patients were enrolled and randomly assigned. Of 150 participants who received selonsertib or placebo, 134 (89%) completed 24 weeks of the randomly assigned treatment; all were on background PAH therapy (138 [92%] on combination therapy). 90 (60%) patients were in functional class II and 60 (40%) in functional class III. Mean baseline pulmonary vascular resistance was 772 (SD 334) dyn·s/cm5. Change in pulmonary vascular resistance was 6·0 dyn·s/cm5 (SD 28·0; n=31) for placebo, and 35·0 (35·4) dyn·s/cm5 (n=35; p=0·21 vs placebo) for 2 mg selonsertib, −28·0 (30·2) dyn·s/cm5 (n=34; p=0·27 vs placebo) for 6 mg selonsertib, and −21·0 (37·9) dyn·s/cm5 (n=36; p=0·60 vs placebo) for 18 mg selonsertib. The most frequent adverse events were headache (17 [15%]), abnormal dreams (eight [7%]), nausea (seven [6%]), and diarrhoea (seven [6%]) in the selonsertib groups, and headache (six [16%]), nausea (five [14%]), and diarrhoea (two [5%]) in the placebo group. Serious adverse events occurred in 23 (20%) of 113 selonsertib-treated patients and seven (19%) of 37 patients who received placebo. Interpretation Selonsertib once daily for 24 weeks did not lead to a significant reduction in pulmonary vascular resistance or to clinical improvement in patients with PAH, but appeared to be safe and well tolerated. Although these data do not support the clinical use of selonsertib in PAH, further study of the potential of targeting the ASK1–p38 pathway in PAH is warranted. Funding Gilead Sciences.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小怪兽完成签到 ,获得积分10
刚刚
科目三应助丢丢丢采纳,获得10
1秒前
英俊的铭应助晴栀采纳,获得10
1秒前
1秒前
elysia完成签到,获得积分10
1秒前
2秒前
6666666666完成签到 ,获得积分10
6秒前
zz完成签到,获得积分10
6秒前
Popeye应助阿胡采纳,获得30
7秒前
8秒前
魁魁完成签到,获得积分20
8秒前
PEKIEOKE发布了新的文献求助30
9秒前
9秒前
无语的凡梦完成签到,获得积分10
10秒前
wanci应助二十四桥明月夜采纳,获得10
11秒前
风清扬应助LaTeXer采纳,获得10
11秒前
leo关闭了leo文献求助
12秒前
推土机爱学习完成签到 ,获得积分10
12秒前
李萍萍发布了新的文献求助10
12秒前
12秒前
fdwang完成签到 ,获得积分10
12秒前
清漪完成签到 ,获得积分10
13秒前
深情安青应助海白采纳,获得10
13秒前
晴栀完成签到,获得积分10
13秒前
hetao286完成签到,获得积分10
14秒前
阿三的风光完成签到 ,获得积分10
14秒前
nature完成签到 ,获得积分10
14秒前
量子星尘发布了新的文献求助10
15秒前
科研狗完成签到 ,获得积分10
16秒前
追光者完成签到,获得积分10
16秒前
HJJHJH发布了新的文献求助10
17秒前
Advance.Cheng发布了新的文献求助10
17秒前
传统的大白完成签到,获得积分10
17秒前
复杂的白秋完成签到,获得积分10
18秒前
18秒前
舒适的平蓝完成签到,获得积分10
19秒前
DAI123完成签到,获得积分10
19秒前
19秒前
阳yang发布了新的文献求助10
19秒前
HIH完成签到 ,获得积分10
20秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038426
求助须知:如何正确求助?哪些是违规求助? 3576119
关于积分的说明 11374556
捐赠科研通 3305834
什么是DOI,文献DOI怎么找? 1819339
邀请新用户注册赠送积分活动 892678
科研通“疑难数据库(出版商)”最低求助积分说明 815029